CRISPR Therapeutics AG
CRSP
Market Cap$4.1B
Close$
$-3.84
107.4% downside
Current Fair Value
107.4% downsideOvervalued by 107.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.10 Billion |
|---|---|
| Enterprise Value | $4.09 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-4.34 |
| Beta | 1.74 |
| Outstanding Shares | 85,938,720 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -10.58 |
|---|---|
| PEG | -63.58 |
| Price to Sales | - |
| Price to Book Ratio | 2.49 |
| Enterprise Value to Revenue | 113.23 |
| Enterprise Value to EBIT | -8.53 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About CRISPR Therapeutics AG
CEO: Samarth Kulkarni